4-(2-苯乙基-1-基)噻吩-2-羧酸 | 175203-58-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(2-苯乙基-1-基)噻吩-2-羧酸
• 英文名称: 4-(phenylethynyl)thiophene-2-carboxyaldehyde
• 英文别名: 4-(phenylethynyl)thiophene-2-carbaldehyde；4-Phenylethynyl-thiophene-2-carbaldehyde；4-(2-Phenyleth-1-ynyl)thiophene-2-carbaldehyde；4-(2-phenylethynyl)thiophene-2-carbaldehyde
• CAS: 175203-58-4
• 化学式: C₁₃H₈OS
• mdl: MFCD00174359
• 分子量: 212.272
• InChiKey: SAYKNBQCVYQQJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090

SDS

Name:	4-(2-Phenyleth-1-ynyl)thiophene-2-carbaldehyde 97% Material Safety Data Sheet
Synonym:	4-(Phenylethynyl)thiophene-2-carboxaldehyd
CAS:	175203-58-4

Section 1 - Chemical Product MSDS Name:4-(2-Phenyleth-1-ynyl)thiophene-2-carbaldehyde 97% Material Safety Data Sheet
Synonym:4-(Phenylethynyl)thiophene-2-carboxaldehyd

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175203-58-4	4-(2-Phenyleth-1-ynyl)thiophene-2-carb	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175203-58-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 118 - 120 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H8OS
Molecular Weight: 212

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175203-58-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(2-Phenyleth-1-ynyl)thiophene-2-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 175203-58-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175203-58-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175203-58-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-苯乙基-1-基)噻吩-2-羧酸 在 甲醇 、 sodium tetrahydroborate 、 硅酸四乙酯 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 2-二苯基膦-联苯 、 sodium hydride 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 16.33h， 生成 2-allyl-5-methyl-3-(phenylethynyl)thiophene
  参考文献：
  名称：

  N-（芳甲基）磺酰亚胺与烯丙基格氏试剂的高度区域选择性芳族 C-H 烯丙基化反应，涉及苄基 C-N 裂解

  摘要：

  已经建立了一对新的反应伙伴，用于通过钯催化的苄基 C-N 裂解将苄基亲电试剂与亲核试剂的芳族 C-H 官能化。一系列N- (1-萘基甲基)磺酰亚胺、N- (2-噻吩基甲基)磺酰亚胺和N- (2-呋喃基甲基)磺酰亚胺在室温下与烯丙基格氏试剂顺利进行钯催化的芳族 C-H 烯丙基化，在结构上传递多种取代的 1-烯丙基萘和 2-烯丙基杂芳烃，产率中等至极好，具有极高的区域选择性。更换N-(芳甲基)磺酰亚胺与(芳甲基)铵盐、芳甲基氯化物或芳甲基磷酸酯作为苄基亲电试剂导致区域选择性的显着侵蚀。

  DOI：

  10.1021/acs.orglett.1c02437
• 作为产物：
  描述：

  4-溴-2-噻吩甲醛 、 苯乙炔 在 copper(l) iodide 、 二(氰基苯)二氯化钯 N,N-二异丙基乙胺 作用下， 反应 16.0h， 以88%的产率得到4-(2-苯乙基-1-基)噻吩-2-羧酸
  参考文献：
  名称：

  FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

  摘要：

  这项发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病，如神经精神病和神经退行性疾病，以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构：其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员，前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员，其中X+是正离子，从无机正离子和有机正离子中选择的成员。

  公开号：

  US20080004327A1

文献信息

• Structure−Activity Relationship Study of Prion Inhibition by 2-Aminopyridine-3,5-dicarbonitrile-Based Compounds:  Parallel Synthesis, Bioactivity, and in Vitro Pharmacokinetics
  作者：Barnaby C. H. May、Julie A. Zorn、Juanita Witkop、John Sherrill、Andrew C. Wallace、Giuseppe Legname、Stanley B. Prusiner、Fred E. Cohen

  DOI：10.1021/jm061045z

  日期：2007.1.1

  2-Aminopyridine-3,5-dicarbonitrile compounds were previously identified as mimetics of dominant-negative prion protein mutants and inhibit prion replication in cultured cells. Here, we report findings from a comprehensive structure-activity relationship study of the 6-aminopyridine-3,5-dicarbonitrile scaffold. We identify compounds with significantly improved bioactivity (approximately 40-fold) against

  2-氨基吡啶-3,5-二甲腈化合物以前被鉴定为显性负病毒蛋白突变体的模拟物，并抑制病毒在培养细胞中的复制。在这里，我们报告从6-氨基吡啶-3,5-二甲腈支架的全面的结构-活性关系研究中发现的结果。我们确定了具有明显改善的生物活性（约40倍）的抗感染性ion病毒同工型（PrPSc）复制和合适的药代动力学特征的化合物，以保证在病毒疾病的动物模型中进行评估。
• Novel compounds and their use
  申请人：——

  公开号：US20020147200A1

  公开（公告）日：2002-10-10

  A compound of the general formula (I): 1 wherein R 1 , R 2 , X, Y and Z are as described in the specification.

  通式（I）的化合物：其中R1、R2、X、Y和Z如规范中所述。
• Tetrahydroquinoline derivatives as antithrombotic agents
  申请人：——

  公开号：US20030225110A1

  公开（公告）日：2003-12-04

  This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa; pharmaceutical compositions containing the same; and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.

  这项发明通常涉及四环四氢喹啉化合物及其类似物，以及其药用盐形式，这些化合物是选择性抑制丝氨酸蛋白酶酶，特别是VIIa因子的；含有同样化合物的药物组合物；以及将其用作抗凝剂调节凝血级联的方法。
• Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
  申请人：The Regents of the University of California

  公开号：US20040014801A1

  公开（公告）日：2004-01-22

  The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.

  本发明涉及硫代半卡巴酮和半卡巴酮对半胱氨酸蛋白酶的抑制剂，以及使用这些化合物预防和治疗原生动物感染，如锥虫病、疟疾和利什曼病的方法。这些化合物还可用于抑制与癌变有关的半胱氨酸蛋白酶，包括卡特普辛B和L。
• [EN] SUBSTITUTED OXADIAZOLIDINEDIONES ALS PAI-1 INHIBITORS<br/>[FR] OXADIAZOLIDINEDIONES SUBSTITUES UTILISES COMME INHIBITEURS DES ALS PAI-1
  申请人：WYETH CORP

  公开号：WO2005030203A1

  公开（公告）日：2005-04-07

  The present invention relates generally to substituted oxadiazolidinediones of the Formula (I); wherein R1 is hydrogen or -(CH2)nCOOH; n is an integer from 1 to 3; X is Formula (A), Formula (B), Formula (C) or Formula (D); as inhibitors of PAI-1.

  本发明涉及一般式(I)的取代噁唑烷二酮，其中R1为氢或-(CH2)nCOOH；n为1至3的整数；X为公式(A)、公式(B)、公式(C)或公式(D)，作为PAI-1的抑制剂。